About Equillium (EQ)

Equillium Inc (EQ) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe autoimmune and inflammatory disorders. With a deep understanding of the immune system and its dysregulation in these diseases, Equillium is committed to improving the lives of patients and advancing the field of immunology. The company's lead product candidate, itolizumab, is currently being evaluated for the treatment of several autoimmune diseases, including acute graft-versus-host disease (aGVHD) and uncontrolled asthma. Itolizumab is a first-in-class monoclonal antibody that selectively targets CD6, a co-stimulatory receptor involved in T cell activation. By modulating the CD6 pathway, Equillium aims to restore immune homeostasis and prevent the destructive immune responses seen in autoimmune disorders.

Equillium's stock price history reflects the growing interest in the company and its potential to deliver innovative therapies. Since its initial public offering in May 2018, the stock has experienced significant fluctuations but has shown an overall upward trend. This is a testament to the market's optimism about Equillium's pipeline and the potential of itolizumab. Investors should note that biopharmaceutical stocks can be volatile, and the price of EQ may be influenced by various factors, including clinical trial results, regulatory approvals, and market conditions. It is always important to conduct thorough research and consult with a financial advisor before making investment decisions.